|
Hematologic toxicities of concurrent chemoradiation in cancer patients at Ubonratchathani cancer hospital |
|---|---|
| รหัสดีโอไอ | |
| Creator | Manit Saeteaw |
| Title | Hematologic toxicities of concurrent chemoradiation in cancer patients at Ubonratchathani cancer hospital |
| Contributor | Thanut Khuayjarernpanishk |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2561 |
| Journal Title | Isan Journal of Pharmaceutical Sciences |
| Journal Vol. | 14 |
| Journal No. | 1 |
| Page no. | 13-20 |
| Keyword | Hematologic toxicities, Concurrent chemoradiation, Cancer patients |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences, IJPS |
| ISSN | 19050852 |
| Abstract | Background: Concurrent Chemoradiation is an important strategy which is recommended in treatment many types of cancer. Hematologic toxicities from Concurrent Chemoradiation are an important drug-related problem are gradually reported. Objectives: The purpose of this study was to evaluate the prevalence of hematologic toxicities of Concurrent Chemoradiation in cancer patients at Ubonratchathani Cancer Hospital Methods: The retrospective cohort study was conducted based on medical records of 127 cancer patients who were treated with Concurrent Chemoradiation between January and June 2012 at Ubonratchathani Cancer Hospital. Incidences of hematologic toxicities including Anemia, Leucopenia, Neutropenia and Thrombocytopenia were collected were analyzed by Descriptive statistic. Hematologic toxicities incidences and hematologic laboratories before and after Concurrent Chemoradiation were compared using McNemar chi-square test and Wilcoxon signed-rank test, respectively. Results: 126 patients (99.2%) have got hematologic toxicities after Concurrent Chemoradiation. There were 21 patients (16.5%) have Grade 3-4 toxicities. Anemia was the most common toxicities. Incidences of hematologic toxicities were significant increased and hematologic laboratories were decreased after Concurrent Chemoradiation (P<0.05). Conclusions: The incidences of hematologic toxicities were significant increased after Concurrent Chemoradiation in concordant to declining hematologic laboratories. |
